Cencora, Inc. $COR Shares Acquired by Swmg LLC

Swmg LLC raised its holdings in shares of Cencora, Inc. (NYSE:COR) by 13.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,414 shares of the company’s stock after acquiring an additional 512 shares during the period. Swmg LLC’s holdings in Cencora were worth $1,263,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Obermeyer Wealth Partners lifted its stake in Cencora by 1.3% during the 1st quarter. Obermeyer Wealth Partners now owns 2,724 shares of the company’s stock valued at $758,000 after acquiring an additional 36 shares during the period. Grove Bank & Trust lifted its stake in Cencora by 4.3% during the 2nd quarter. Grove Bank & Trust now owns 879 shares of the company’s stock valued at $264,000 after acquiring an additional 36 shares during the period. U.S. Capital Wealth Advisors LLC lifted its stake in Cencora by 0.4% during the 2nd quarter. U.S. Capital Wealth Advisors LLC now owns 8,547 shares of the company’s stock valued at $2,563,000 after acquiring an additional 38 shares during the period. Monument Capital Management increased its holdings in shares of Cencora by 2.4% during the 2nd quarter. Monument Capital Management now owns 1,637 shares of the company’s stock valued at $491,000 after purchasing an additional 38 shares in the last quarter. Finally, Cromwell Holdings LLC increased its holdings in shares of Cencora by 9.5% during the 1st quarter. Cromwell Holdings LLC now owns 450 shares of the company’s stock valued at $125,000 after purchasing an additional 39 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CEO Robert P. Mauch sold 5,097 shares of the company’s stock in a transaction on Thursday, September 18th. The shares were sold at an average price of $290.00, for a total transaction of $1,478,130.00. Following the completion of the sale, the chief executive officer owned 39,274 shares of the company’s stock, valued at $11,389,460. This represents a 11.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Chairman Steven H. Collis sold 31,350 shares of the company’s stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the sale, the chairman directly owned 305,913 shares of the company’s stock, valued at $88,671,942.18. The trade was a 9.30% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 51,025 shares of company stock valued at $14,831,784 in the last ninety days. Insiders own 10.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Wall Street Zen lowered shares of Cencora from a “buy” rating to a “hold” rating in a report on Saturday, October 11th. Morgan Stanley set a $330.00 target price on shares of Cencora and gave the company an “equal weight” rating in a report on Wednesday, July 16th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Cencora in a report on Wednesday, October 8th. Jefferies Financial Group lifted their target price on shares of Cencora from $275.00 to $300.00 and gave the company a “hold” rating in a report on Monday, June 30th. Finally, Evercore ISI set a $340.00 target price on shares of Cencora in a report on Wednesday, October 8th. Nine analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $324.91.

Cencora Price Performance

Shares of NYSE COR opened at $324.83 on Friday. The firm has a market cap of $62.98 billion, a PE ratio of 33.42, a PEG ratio of 1.52 and a beta of 0.63. The firm has a fifty day moving average of $300.30 and a 200 day moving average of $293.23. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90. Cencora, Inc. has a one year low of $223.92 and a one year high of $325.70.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $4.00 EPS for the quarter, topping the consensus estimate of $3.79 by $0.21. The company had revenue of $80.66 billion during the quarter, compared to analyst estimates of $80.34 billion. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The firm’s revenue was up 8.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.34 EPS. As a group, research analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Friday, August 15th were issued a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend was Friday, August 15th. Cencora’s payout ratio is presently 22.63%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.